- Home
- KPRX vs LCFY Comparison
KPRX vs LCFY Comparison
Compare KPRX & LCFY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- LCFY
- Stock Information
- Founded
- KPRX 1998
- LCFY 2009
- Country
- KPRX United States
- LCFY Australia
- Employees
- KPRX N/A
- LCFY N/A
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- LCFY
- Sector
- KPRX Health Care
- LCFY
- Exchange
- KPRX Nasdaq
- LCFY Nasdaq
- Market Cap
- KPRX 9.2M
- LCFY 9.2M
- IPO Year
- KPRX N/A
- LCFY 2022
- Fundamental
- Price
- KPRX $2.15
- LCFY $3.73
- Analyst Decision
- KPRX Strong Buy
- LCFY
- Analyst Count
- KPRX 1
- LCFY 0
- Target Price
- KPRX $10.00
- LCFY N/A
- AVG Volume (30 Days)
- KPRX 53.1K
- LCFY 20.6K
- Earning Date
- KPRX 11-07-2025
- LCFY 11-12-2025
- Dividend Yield
- KPRX N/A
- LCFY N/A
- EPS Growth
- KPRX N/A
- LCFY N/A
- EPS
- KPRX N/A
- LCFY N/A
- Revenue
- KPRX N/A
- LCFY $2,313,843.00
- Revenue This Year
- KPRX N/A
- LCFY N/A
- Revenue Next Year
- KPRX N/A
- LCFY N/A
- P/E Ratio
- KPRX N/A
- LCFY N/A
- Revenue Growth
- KPRX N/A
- LCFY N/A
- 52 Week Low
- KPRX $2.05
- LCFY $2.51
- 52 Week High
- KPRX $4.18
- LCFY $13.98
- Technical
- Relative Strength Index (RSI)
- KPRX 33.03
- LCFY 22.31
- Support Level
- KPRX $2.26
- LCFY $3.80
- Resistance Level
- KPRX $2.39
- LCFY $4.12
- Average True Range (ATR)
- KPRX 0.14
- LCFY 0.27
- MACD
- KPRX -0.02
- LCFY -0.02
- Stochastic Oscillator
- KPRX 16.03
- LCFY 2.08
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About LCFY Locafy Limited
Locafy Ltd is focused on commercializing its Software as a Service (SaaS) online publishing technology platform. Its platform enables the ability to publish almost any type of content to almost any device that uses a web browser to display web content. The firm has two operating segments: Publishing and SEO agency. Under the Publishing segment are products and services that the Company offers that are related to digital properties (i.e. mastheads) that it owns e.g. business data published on Hotfrog, advertising placed on AussieWeb, articles published on scoop.com.au. In contrast, under the SEO Agency segment are products and services that are applied to digital properties that are owned and operated by third parties. It derives a majority of its revenue in North America from SEO Agency.